Home > Healthcare > Pharmaceuticals > Finished Drug Form > Abortion Drugs Market

Abortion Drugs Market Trends

Report ID: GMI8059
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Abortion Drugs Market Trends

Medication abortion has gained acceptance globally as an alternative to surgical procedures. This trend is driven by the perceived safety and efficacy of these medications in terminating early pregnancies. Therefore, initiatives aimed at educating the public about reproductive health, contraceptives, and abortion options plays a crucial role. Informed decision-making is encouraged through comprehensive education, reducing the stigma associated with abortion, and fostering a better understanding of available options.

Healthcare infrastructure improvements and increased awareness campaigns in developing countries have expanded access to reproductive health services, including abortion drugs. The market is witnessing growth in regions wherein such services were historically less accessible.
International organizations and health initiatives focused on reproductive health and family planning contribute to the accessibility of abortion drugs. Efforts to reduce maternal mortality rates often involve making safe abortion services, including medication abortion, more widely available.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market size for abortion drugs was valued at around USD 24.4 billion in 2023 and is estimated to reach USD 49.3 billion by 2032, at a CAGR of 8.2%, driven by improving awareness about reproductive health and abortion options.

The mifepristone drug class segment is poised for significant growth at 8.6% through 2032, owing to its efficacy and non-invasive nature.

North America abortion drugs industry accounted for USD 11.1 billion in 2023 and is predicted to witness substantial growth over 2024 and 2032, driven by a favorable legal and regulatory environment.

Cipla Limited, Endo International plc, Exelgyn, Gedeon Richter plc, Jubilant Life Sciences, Lupin Limited, Mylan N.V., Pfizer Inc., Sun Pharmaceutical Industries, Torrent Pharmaceuticals Ltd., Zydus Lifesciences Limited are some of the major industry contenders.